Detalhe da pesquisa
1.
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.
N Engl J Med
; 2024 May 25.
Artigo
Inglês
| MEDLINE | ID: mdl-38804514
2.
Predictors of graft failure after first detection of de novo donor-specific HLA antibodies in kidney transplant recipients.
Nephrol Dial Transplant
; 39(1): 84-94, 2023 Dec 20.
Artigo
Inglês
| MEDLINE | ID: mdl-37410616
3.
Donor-Derived Cell-Free DNA for Kidney Allograft Surveillance after Conversion to Belatacept: Prospective Pilot Study.
J Clin Med
; 12(6)2023 Mar 22.
Artigo
Inglês
| MEDLINE | ID: mdl-36983437
4.
The natural history of de novo donor-specific HLA antibodies after kidney transplantation.
Front Med (Lausanne)
; 9: 943502, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36186822
5.
Absolute or Relative Quantification of Donor-derived Cell-free DNA in Kidney Transplant Recipients: Case Series.
Transplant Direct
; 7(11): e778, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34712778
6.
Donor-Derived Cell-Free DNA in Biopsy-Proven Antibody-Mediated Rejection Versus Recurrent IgA Nephropathy After Kidney Transplantation.
Kidney Int Rep
; 8(10): 2141-2145, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37849995